The ABCs on CBD Oil: NuLeaf Naturals Review

Updated: Jan 30, 2020

CBD oil is all the rage right now, but it’s also largely unregulated in the US, so you need to know what to look for before you buy.

My top priority as a consumer is to research a company I'm considering to purchase from and understand their mission to ensure it’s inline with mine. Once, I’ve checked that box, I can start digging into the ingredients, sourcing methods, and if I have questions, speak to their product specialists to vet their credibility.

CBD for me...and my pugs

When it comes to CBD oil, I absolutely love NuLeaf Naturals. It’s offered in a variety of different strengths and I use it internally and topically, when needed.

NuLeaf Naturals CBD Oil

CBD oil helps me maintain mental focus and reduces my stress levels almost immediately. I also notice it calms my pugs when I give it to them before a road trip or an especially stressful situation. It also helps me get better quality sleep (especially when coupled with an epsom salt bath), and while I don't necessarily have anxiety or social anxiety, I do like to take it before social gatherings to take the edge off.For my pugs, I use Nuleaf and/or Pet Releaf. I believe Nuleaf to be the highest quality CBD oil on the market. They have a third-party test the purity of their product and they grow their hemp on a Certified USDA Organic hemp farm in the United States, which is the only pet company the USDA works with.

No matter what brand you’re looking into, just be sure to research the following:

  1. What’s the extraction method?

  2. What/where is the CBD oil sourced from?

  3. Is there third-party testing to ensure potency and test for contaminants?

  4. What are the ingredients? Are there fillers? Synthetics?

Check out more ways to reduce and eliminate anxiety


1. Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 12(4), 825–836. doi:10.1007/s13311-015-0387-1